Shujun Luo

Shujun Luo has extensive work experience in the field of genomics and sequencing. Starting in 1997, Luo worked as a Staff Scientist at Lynx Therapeutics, where they developed MPSS chemistry and various sample prep methods for MPSS sequencing. Luo then joined Solexa (later acquired by Illumina) as a Senior Staff Scientist, where they played a pivotal role in developing Chip-Seq, Digital tag sequencing, and methods for measuring DNaseI hypersensitive sites and detecting microRNA targets using next-gen sequencing technology. Luo also worked as a Senior Staff Scientist at Illumina, leading the development of RNA-Seq, smallRNA-Seq, and Smart-seq methods for single-cell transcriptome analysis. Additionally, Luo developed HiTS-FLIP, a method to measure protein-DNA interaction using next-gen sequencing, with results published in Nature Biotechnology.

In 2012, Luo joined Personalis, Inc. as the Director of Lab Operation and R&D. There, Luo built the entire laboratory R&D and operation team/facility and developed the Personalis ACE platform for exome and panel sequencing. Luo also led the R&D effort to develop the ImmunoID NeXT Platform, a comprehensive platform enabling TCR/BCR repertoire profiling, neoantigen detection, and other tumor analyses. During their tenure, Luo collaborated with marketing, product development, and bioinformatics teams for the commercial launch of the ImmunoID NeXT platform.

Following their time at Personalis, Luo joined Zymergen as the Sr Director of Genomics and Sequencing Core in 2019. There, they built an NGS core laboratory capable of processing 1 million samples per year and led the NGS team in developing functional genomic and metagenomic methods. Luo also played a strategic role in planning companywide projects.

Most recently, Luo joined Predicine in 2020. Shujun initially served as the Vice President of R&D, leading laboratory teams and overseeing operations. During this time, Luo successfully developed liquid biopsy-based NGS assays for cfDNA, cfRNA, and methylation analysis, with a key product granted breakthrough device designation by the US Food and Drug Administration. Luo has since been promoted to Senior Vice President of R&D.

Shujun Luo has a Master's degree in Cell/Cellular and Molecular Biology from Columbia University. Prior to that, they earned a Bachelor's degree in the same field from the University of Science and Technology of China.